Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02656069 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics
A Phase 3 study, sponsored by Xeris Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
NCT02656069 is a Phase 3 study that has completed, run by Xeris Pharmaceuticals. The registered enrollment target is 80 participants.
The verdict
NCT02656069, a Phase 3 study, has completed, sponsored by Xeris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
Study Summary
This is a blinded, randomized crossover study to compare the safety and efficacy of G-Pen (glucagon injection) to Lilly Glucagon (glucagon for injection \[rDNA origin\]) for hypoglycemia rescue of adult patients with type 1 diabetes.
Interventions
- DRUG G-Pen (glucagon injection)
- DRUG Lilly Glucagon (glucagon injection [rDNA origin])
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2017-09-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02656069
The ClinicalTrials.gov registry entry for NCT02656069 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xeris Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which G-Pen (glucagon injection) is the first listed.
NCT02656069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02656069 about?
NCT02656069 is a clinical study titled "Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics". This is a blinded, randomized crossover study to compare the safety and efficacy of G-Pen (glucagon injection) to Lilly Glucagon (glucagon for injection \[rDNA origin\]) for hypoglycemia rescue of adult patients with type 1 diabetes.
What is the current status of trial NCT02656069?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2017-03-15. Estimated completion is 2017-09-25.
What interventions are being tested in trial NCT02656069?
The interventions under investigation include: G-Pen (glucagon injection) (DRUG), Lilly Glucagon (glucagon injection [rDNA origin]) (DRUG).
Who is sponsoring clinical trial NCT02656069?
This trial is sponsored by Xeris Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.